Mergers and Acquisition | Veristrat LLC | What's Your Valuation?

Important Links About Us Contact Us Merger & Acquisition Raising Capital Estate Planning Crypto & NFT Sitemap

2.48 Rating by Usitestat

veristrat.com was registered 1 decade 7 years ago. It has a alexa rank of #1,959,995 in the world. It is a domain having .com extension. It is estimated worth of $ 720.00 and have a daily income of around $ 3.00. As no active threats were reported recently, veristrat.com is SAFE to browse.

Updated 2 years 11 months ago

Traffic Report

Daily Unique Visitors:	447
Daily Pageviews:	894

Estimated Valuation

Income Per Day:	$ 3.00
Estimated Worth:	$ 720.00

Search Engine Indexes

Google Indexed Pages:	Not Applicable
Yahoo Indexed Pages:	Not Applicable
Bing Indexed Pages:	Not Applicable

Search Engine Backlinks

Google Backlinks:	Not Applicable
Bing Backlinks:	Not Applicable
Alexa BackLinks:	Not Applicable

Safety Information

Google Safe Browsing:	No Risk Issues
Siteadvisor Rating:	Not Applicable
WOT Trustworthiness:	Very Poor
WOT Privacy:	Very Poor
WOT Child Safety:	Very Poor

Website Ranks & Scores

Alexa Rank:	1,959,995
PageSpeed Score:	89 ON 100
Domain Authority:	49 ON 100
Bounce Rate:	Not Applicable
Time On Site:	Not Applicable

Web Server Information

Hosted IP Address:

195.201.96.252

Hosted Country:

Location Latitude:

48.3233

Location Longitude:

11.6012

Traffic Classification

Total Traffic:	No Data
Direct Traffic:	No Data
Referral Traffic:	No Data
Search Traffic:	No Data
Social Traffic:	No Data
Mail Traffic:	No Data
Display Traffic:	No Data

Search Engine Results For veristrat.com

Investor Connect: Bharat Kanodia of Veristrat

- https://investorconnect.org/investor-connect-bharat-kanodia-of-veristrat/

Jul 2, 2021 ... Veristrat is a professional services company, headquartered in Pleasanton, California. They provide various valuation and advisory services.

What's it Worth? (@whatsitworthtv) / Twitter

- https://twitter.com/whatsitworthtv

We at Veristrat are working on project to analyze linking between financial statements. Income statement and Balance sheet make up the Cash flow statement.

The clinical role of VeriStrat testing in patients with ... - PubMed

- https://pubmed.ncbi.nlm.nih.gov/31499384/

However, VeriStrat was an independent prognostic marker of survival. It represents an objective measurement that could be considered alongside other patient ...

Evaluation of VeriStrat, a serum proteomic test, in the randomized ...

- https://www.annalsofoncology.org/article/S0923-7534(19)44861-8/fulltext

Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line ...

Biodesix Announces New Clinical Data Demonstrating VeriStrat ...

- https://www.businesswire.com/news/home/20190918005212/en/Biodesix-Announces-New-Clinical-Data-Demonstrating-VeriStrat-Testing-Predicts-Survival-in-Advanced-NSCLC-and-Immunotherapy

Sep 18, 2019 ... Positive results from multiple studies support clinical utility of VeriStrat testing in advanced NSCLC and immunotherapy.

The clinical role of VeriStrat testing in patients with ... -...

- https://www.sciencedirect.com/science/article/pii/S0959804919304447

VeriStrat (proteomic blood test) is an independent prognostic marker for survival. •. Patients classified as VeriStrat Good were less likely to die than those ...

VeriStrat® has prognostic value in advanced stage NSCLC patients ...

- https://www.nature.com/articles/bjc2012470

Oct 18, 2012 ... The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall ...

Prediction of the VeriStrat test in first-line therapy of...

- https://cancerci.biomedcentral.com/articles/10.1186/s12935-020-01662-5

Dec 9, 2020 ... Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed ...

Correlating the effects of VeriStrat result, anti-PD1 therapy, and ...

- https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e20660

May 26, 2019 ... e20660Background: Biodesix VeriStrat (VS) is a mass spectrometry assay found to be prognostic in previously treated and front-line NSCLC ...

Clinical Effectiveness Assessment of VeriStrat® Testing and ...

- https://clinicaltrials.gov/ct2/show/NCT03289780

Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study ...

Mergers and Acquisition | Veristrat LLC | What's Your Valuation?

- https://www.veristrat.com/

Nov 20, 2021 ... Mergers and Acquisitions & Venture Capital Valuation... Veristrat is an industry-leading expert in valuations.

Lung Cancer - HubSpot

- https://cdn2.hubspot.net/hubfs/5816323/downloads/Grossi_et_al.pdf

The prognostic properties of VeriStrat were demonstrated in the placebo arms of two randomized studies in non-small cell lung cancer (NSCLC): TOPICAL and BR.21; ...

Study Confirms Prognostic Value of Biodesix VeriStrat Test in ...

- https://www.clinicalomics.com/topics/oncology/study-confirms-prognostic-value-of-biodesix-veristrat-test-in-nsclc-patients/

Aug 29, 2018 ... Biodesix said today that its VeriStrat proteomic blood test has shown its prognostic value for patients with non-small cell lung cancer ...

PROTEOMIC TESTING FOR NON SMALL-CELL LUNG CANCER ...

- https://www.bcbsm.com/amslibs/content/dam/public/mpr/mprsearch/pdf/2037144.pdf

May 1, 2021 ... Title: Proteomic Testing for Targeted Therapy in Non-Small-Cell. Lung Cancer (NSCLC), e.g., VeriStrat®. Description/Background.

Bharat Kanodia's Articles | Inc.com

- https://www.inc.com/author/Bharat-Kanodia

Bharat is the Founder and Chief Appraiser of Veristrat. Veristrat offers valuations and M&A readiness solutions for business owners and investors.

Biodesix, Inc. BDX-00146 - Omaha - Methodist Health System

- https://bestcare.org/clinical-trials/lung-cancer/biodesix-inc-bdx-00146

An observational study assessing the clinical effectiveness of the VeriStrat test and validation immunotherapy tests in subjects with non-small cell lung ...

Edison, NJ Archives - Regional Cancer Care Associates

- https://www.regionalcancercare.org/rcca_clinic/edison-nj/

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer.

Randomized Phase III Trial of Erlotinib versus Docetaxel in...

- https://research.rug.nl/en/publications/randomized-phase-iii-trial-of-erlotinib-versus-docetaxel-in-patie

NSCLC · Squamous · Erlotinib · Docetaxel · ETOP · VeriStrat · TYROSINE KINASE INHIBITORS · GROWTH-FACTOR RECEPTOR ...

Positive Bioscience to offer Biodesix's cancer tests in India

- https://www.medicaldevice-network.com/news/newspositive-bioscience-to-offer-biodesixs-cancer-tests-in-india-5842642/

Jun 13, 2017 ... According to the findings from clinical studies of the VeriStrat test, to allow treatment decisions, the classification as VeriStrat-Good or ...

2.04.125 Proteomic Testing for Systemic Therapy in Non-Small Cell ...

- https://www.premera.com/medicalpolicies/2.04.125.pdf

Feb 1, 2021 ... VeriStrat® assay, is considered investigational for all uses in the management of non-small cell lung cancer. Coding. Code. Description.

Prognostic role of the VeriStrat test in first line patients with...

- https://www.lungcancerjournal.info/article/S0169-5002(17)30614-1/fulltext

Dec 13, 2017 ... VeriStrat Poor patients have poor prognosis on standard first line chemotherapy. •. Those patients should consider clinical trials and other ...

Biodesix Announces Publication Highlighting Interim Data from the ...

- https://www.biospace.com/article/releases/biodesix-announces-publication-highlighting-interim-data-from-the-insight-study-assessing-the-clinical-effectiveness-of-veristrat-proteomic-test-in-the-journal-of-immunotherapy-of-cancer/

Nov 18, 2021 ... Data published shows the VeriStrat proteomic test improved overall patient survival by better informing physicians on the selection of ...

Page Resources Breakdown